Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Interleukin-15 receptor agonists
11 evidence topics · 6 sources
FDA-approved indication and mechanism: nogapendekin alfa inbakicept-pmln with BCG
Dosage and administration with BCG
Expanded indication to papillary-only disease by extrapolation, October 2026
QUILT-3.032 Cohort A: design and population
QUILT-3.032 Cohort A: efficacy in the prescribing information
| Endpoint | Nogapendekin alfa inbakicept-pmln with TICE BCG |
|---|---|
| Participants | “n=77” |
| Complete response rate (95% CI) | “62% (51, 73)” |
| Duration of response, range in months | “0.0, 47.0+” |
| Duration of response ≥12 months, % (n) | “58% (28)” |
| Duration of response ≥24 months, % (n) | “40% (19)” |
| Basis of duration of response | “Based on 48 patients that achieved a complete response at any time” |
QUILT-3.032 Cohort A: long-term follow-up in 100 participants
“Participants received 400 mcg NAI in combination with 50 mg BCG through intravesical instillation weekly for 6 weeks, with optional reinduction if complete response (CR) was not achieved at month 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CR rate (n = 100) was 71% (95% CI 61.1-79.6) with a median duration of CR of 26.6 months (range 0.03-53.62).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This included 56 participants who responded to the initial induction treatment and 15 participants receiving reinduction treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Kaplan-Meier estimated cystectomy-free rate in the 71 responders at 24 and 36 months was 90.3% (95% CI 79.7-95.6) and 84.2% (95% CI 69.6-92.1), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
QUILT-3.032 Cohort B: papillary-only disease
“NCT03022825 is an open-label, multicenter study of patients with BCG-unresponsive high-grade Ta/T1 papillary nonmuscle-invasive bladder cancer who received 400 μg NAI plus 50 mg BCG intravesically weekly for 6 consecutive weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point is disease-free survival (DFS) at 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At July 15, 2024, data cutoff, the DFS rates at 12, 24, and 36 months were 58.2% (95% CI: 46.6, 68.2), 52.1% (95% CI: 40.3, 62.7), and 38.2% (95% CI: 25.6, 50.6), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cystectomy avoidance rates at 12 and 36 months were 92.2% (95% CI: 83.4, 96.4) and 81.8% (95% CI: 68.1, 90.1), with median time to cystectomy not reached.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
European guideline summary of QUILT-3.032
FDA review: contribution of each component of the combination
“Cohort C (N-803 as a single agent) was closed early due to futility based on 10 patients; CRR was 20% [95% CI: 3, 56] with only 1 patient with a durable CR ≥ 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CRR with BCG was 14% [95% CI: 2, 43], indicating that the response rate observed with the combination of N-803 and BCG did not appear to be due solely to the activity of BCG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TICE BCG was the only strain studied in QUILT-3.032 and is currently the only approved BCG strain marketed in the U.S.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote